Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

Phenoconversion from probable rapid eye movement sleep
behavior disorder to mild cognitive impairment to dementia in a
population-based sample
Youngsin Jung
Mayo Clinic

Brendon P. Boot
Brigham and Women's Hospital

Michelle M. Mielke
Mayo Clinic

Tanis J. Ferman
Mayo Clinic

Yonas E. Geda
Mayo Clinic

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Jung, Youngsin; Boot, Brendon P.; Mielke, Michelle M.; Ferman, Tanis J.; Geda, Yonas E.; McDade, Eric;
Christianson, Teresa J.H.; Knopman, David S.; St Louis, Erik K.; Silber, Michael H.; Petersen, Ronald C.; and
Boeve, Bradley F., ,"Phenoconversion from probable rapid eye movement sleep behavior disorder to mild
cognitive impairment to dementia in a population-based sample." Alzheimer's & Dementia: Diagnosis,
Assessment & Disease Monitoring. 8,. 127-130. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5961

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Youngsin Jung, Brendon P. Boot, Michelle M. Mielke, Tanis J. Ferman, Yonas E. Geda, Eric McDade, Teresa
J.H. Christianson, David S. Knopman, Erik K. St Louis, Michael H. Silber, Ronald C. Petersen, and Bradley F.
Boeve

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/5961

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 127-130

Diagnostic Assessment & Prognosis
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Abstract

Introduction: Rapid eye movement sleep behavior disorder (RBD) is strongly associated with synucleinopathies. In 2012, we reported an increased risk of mild cognitive impairment (MCI) and Parkinson
disease (PD) in cognitively normal Olmsted County, Minnesota, residents, aged 70 to 89 years with probable RBD. Here, we examine their progression to dementia and other neurodegenerative phenotypes.
Methods: Fifteen participants with RBD who were diagnosed with either MCI or PD were longitudinally followed, and their subsequent clinical courses were reviewed.
Results: Over 6.4 6 2.9 years, six of the 14 participants with MCI developed additional neurodegenerative signs, five of whom had Lewy body disease features. Four of them progressed to dementia at a
mean age 84.8 6 4.9 years, three of whom met the criteria for probable dementia with Lewy bodies.
One subject with PD developed MCI, but not dementia.
Discussion: Our findings from the population-based sample of Olmsted County, Minnesota, residents suggest that a substantial number of RBD patients tend to develop overt synucleinopathy features over time, and RBD patients who develop MCI and subsequent dementia have clinical features
most consistent with dementia with Lewy bodies.
Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Rapid eye movement sleep behavior disorder (RBD) is a
parasomnia characterized by complex motor behaviors (e.g.,
shouting, screaming, kicking, and punching) suggestive of
*Corresponding author. Tel.: 11 507-538-1038; Fax: 11 507-5386012.
E-mail address: bboeve@mayo.edu

dream enactment [1]. The prevalence of RBD increases in
older adults, especially in those with neurodegenerative conditions [2,3]. In particular, RBD is strongly associated with
synucleinopathies, including Parkinson disease (PD),
dementia with Lewy bodies (DLB), and multiple system
atrophy [4,5]. Longitudinal cohort studies of patients with
idiopathic RBD suggest that most of these patients
ultimately develop an overt neurodegenerative phenotype

http://dx.doi.org/10.1016/j.dadm.2017.05.004
2352-8729/ Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with the rate of phenoconversion as high as 91% at 14 years
[6–8]. However, these studies are based on sleep center
cohorts in which referral bias toward more severe disease
is likely to be present, and therefore may not reflect
findings in the general population.
To assess population-based risk of neurodegenerative disease in RBD, we previously studied cognitively normal individuals aged 70 to 89 years with probable RBD (pRBD) in
Olmsted County, Minnesota, and reported a 2.2-fold–
increased risk of developing mild cognitive impairment
(MCI) or PD over 4 years [3]. Since the initial report, we
have longitudinally followed the participants with pRBD
who developed MCI or PD as part of the Mayo Clinic Study
of Aging (MCSA), a longitudinal population-based study of
aging [9]. Here, we examine their progression to dementia
and other neurodegenerative phenotypes.

2. Methods
The details of subject recruitment and diagnostic evaluation are described in our previous report [3]. Briefly, the original cohort included the MCSA participants aged 70 to
89 years who were randomly selected residents of Olmsted
County, Minnesota, using the medical records linkage system of the Rochester Epidemiology Project. All individuals
in the original cohort were cognitively normal without PD at
the time of their initial enrollment in the MCSA. These participants were longitudinally followed based on a standardized protocol [9]. The diagnosis of pRBD was made using
the Mayo Sleep Questionnaire [10]. A consensus diagnosis
of MCI, dementia, or PD was made according to our previously published criteria [9].
A total of 15 participants with pRBD who were diagnosed
with either MCI or PD at the time of our original analysis

were included in the present study. Follow-up and autopsy
data were obtained from the MCSA and/or review of their
medical records.
Informed consent was obtained from the participants and
their family members or significant others. All study protocols were approved by the Mayo Clinic and Olmsted Medical Center institutional review boards.

3. Results
The demographic and clinical characteristics of the participants are summarized in the Table 1. The participants
were followed for an average 6.4 6 2.9 years after their
MCI or PD diagnosis. Of the 14 participants with MCI,
four with amnestic MCI developed dementia at a mean
age 84.8 6 4.9 years: three met the criteria for probable
DLB [11] and one for Alzheimer disease dementia [12].
The estimated onset of dementia began 13.8 6 6.2 years
after pRBD diagnosis and 4.3 6 2.8 years after MCI diagnosis. All participants with probable DLB had well-formed
visual hallucinations, and one of them also had parkinsonism. One participant with nonamnestic MCI developed
visual hallucinations 2 years after the MCI diagnosis and
another developed parkinsonism 4 years after the MCI
diagnosis, but neither met criteria for dementia. One participant with PD subsequently developed nonamnestic multidomain MCI 10 years after the PD diagnosis. The
remainder of the participants continued to have MCI until
their death or last follow-up (5.9 6 2.9 years), except for
one who was reclassified as having normal cognition 7
years before her death and remained cognitively normal
until the death. Her prior cognitive insufficiency was presumed related to suboptimally controlled depression and/
or polypharmacy. This individual underwent autopsy and

Table 1
Demographic and clinical characteristics of the updated probable RBD cohort
Subject Sex

Age at the onset Age at the onset MCI
of RBD (year)
of MCI (year)
type

Age at the onset
Age at death Age at last
of dementia (year) Dementia type (year)
follow-up (year) Other features

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

71
63
78
72
32
66
23
82
71
69
84
27
30
47
34

84
85
91
79
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

Male
Male
Female
Male
Female
Male
Male
Male
Male
Male
Female
Male
Male
Male
Male

77
84
85
76
82*
87
85
84
81
74
86
78
78
76
84

A
A
A
A
n/a
A
A
A
A, M
A, M
NA
NA
NA
NA, M
U

Probable DLB
Probable DLB
Probable DLB
Probable AD
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

85
89
n/a
81
91
88
n/a
n/a
85
n/a
89
84
n/a
78
87

n/a
n/a
92
n/a
n/a
n/a
93
93
n/a
82
n/a
n/a
86
n/a
n/a

VH, parkinsonism
VH
VH

VH
Parkinsonism
PD

Abbreviations: A, amnestic; AD, Alzheimer disease; DLB, dementia with Lewy bodies; M, multidomain; MCI, mild cognitive impairment; n/a, not applicable; NA, nonamnestic; PD, Parkinson disease; RBD, rapid eye movement sleep behavior disorder; U, unknown type; VH, visual hallucinations.
*Classification changed from amnestic MCI to normal 7 years before her death.
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was found to have neither Lewy body disease nor Alzheimer pathology. No other participant underwent autopsy.

4. Discussion
In our pRBD cohort ascertained in a population-based
sample, six of the 14 MCI participants developed additional
neurodegenerative signs, five of whom had Lewy body disease features, including visual hallucinations and parkinsonism. Three of the four participants who progressed to
dementia satisfied the criteria for probable DLB. Our findings from the population-based sample of Olmsted County,
Minnesota, residents are consistent with the findings from
the previous studies of sleep center cohorts [6–8] and
suggest that RBD patients tend to develop overt
synucleinopathy features when followed over time, and
those RBD patients who develop MCI and subsequent
dementia have clinical features most consistent with DLB.
Potential limitations of our findings include use of a questionnaire for RBD diagnosis. We used the Mayo Sleep Questionnaire, which has a high sensitivity and specificity for
RBD diagnosis in older adults relative to RBD diagnosis
by polysomnography [10]. This lends confidence to RBD
ascertainment despite absence of polysomnographic confirmation, which was not feasible in this population-based
cohort. Another limitation was that our participants were
older adults with an average age of 81 years at the time of
their MCI diagnosis. Most participants died of causes unrelated to their neurodegenerative conditions. This, in turn,
limited our longitudinal follow-up, which may have resulted
in underestimation of the proportion progressing to dementia. Plus, pathologic confirmation of underlying Lewy body
disease in this cohort is lacking either because the subjects
are still alive or autopsy was not performed in those who
have died. However, our population-based design heightens
the generalizability of these findings. We plan future longitudinal studies of younger cohorts with pRBD and MCI to
provide further insight into progression to dementia,
including neuropathologic examination when feasible.
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RESEARCH IN CONTEXT

1. Systematic review: Literature review was done using
traditional search engines (e.g., PubMed/Medline,
Google scholar). Several longitudinal studies of
sleep center cohorts have suggested an increased
risk of neurodegenerative disorders in patients with
idiopathic rapid eye movement sleep behavior disorder (RBD), but population-based risk assessment has
been limited. Our previous population-based study of
individuals with probable RBD showed an increased
risk of mild cognitive impairment and Parkinson
disease, but the duration of follow-up was limited.
We sought to further explore whether other neurodegenerative phenotypes develop in these patients.
2. Interpretation: Our findings provide further evidence
for the association between RBD and synucleinopathies in a population-based sample and suggest
most RBD patients who develop mild cognitive
impairment and subsequent dementia have clinical
features most consistent with dementia with Lewy
bodies.
3. Future directions: Longitudinal studies of younger
cohorts with RBD will provide further insight into
progression to dementia.
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